Prostate cancer Archives - Page 30 of 32 - Sperling Prostate Center

Prostate Cancer: How Traumatic Is It?

How Traumatic is Prostate Cancer - Sperling Prostate Center

What comes to mind when you hear the expression “post traumatic stress disorder” or PTSD? Perhaps it conjures up images of war veterans, crime victims, or natural disasters. We recognize that when something beyond a person’s control creates sudden or catastrophic harm, the person is shaken by it, often deeply. Trauma is defined as a keep reading

Good News for Castration Resistant Prostate Cancer (CRPC) Patients

If you’re wondering what “castration resistant prostate cancer (CRPC)” is, so are many others. Before I write about the good news, I want to back up and talk about what this means. Prostate cancer and testosterone The most newly diagnosed prostate cancer (PCa) cases are composed of slow-growing cell lines. They are typically discovered while keep reading

Prostate Cancer Drugs Are Linked to Dementia

Men need testosterone, but prostate cancer does not. While there is new evidence that use of testosterone replacement therapy does not lead to prostate cancer, once prostate cancer has occurred, it appears to be fueled by testosterone. This is particularly bad news if prostate cancer has penetrated the edges of the gland capsule and begun keep reading

Multiparametric MRI Before Prostate Biopsy: Dawn of a New Era

“Change is inevitable. Progress is optional.” Tony Robbins In medicine, change sometimes happens with two steps forward but one step back. For example, in the early 20th century, delivering babies in hospitals became more popular than home births in order to have “painless” births with anesthesia. However, for many women the higher complication and infection keep reading

Less Expensive MRI Rules Out Unnecessary Prostate Biopsy

Two problems face men who have a high PSA or abnormal digital rectal exam (DRE). First, they are often referred for a conventional TRUS needle biopsy of the prostate because there is suspicion of prostate cancer (PCa). Second, multiparametric MRI is considered too time-consuming and expensive for routine determination of the need for a biopsy. keep reading

How to Detect Cancer in Large Prostate Glands

There are so many benefits to detecting prostate cancer (PCa) using multiparametric MRI that it’s hard to single out just one. However, the merits of mpMRI to find PCa in large glands deserve a spotlight. First, a word about prostate size. An average adult gland in younger men is about 30 – 40cc, roughly the keep reading

Why Choose the Sperling Prostate Center for Active Surveillance?

With Active Surveillance on the rise, one would think that doctors who support AS for their prostate cancer patients have similar commitment and protocols. A new study (Sep. 2016) in the British Journal of Urology International (BJUI) spells out 8 areas of qualitative differences among AS doctors: physician comfort with active surveillance protocol selection beliefs keep reading

British Study Confirms the Role of mpMRI Before Biopsy

Terrific news and a great way to start off 2017! On January 17, the prestigious medical journal The Lancet issued online publication of a British study, “Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study” (Ahmed et al., 2017[i]). This large trial validated the importance of multiparametric keep reading

MRI Outperforms PHI for Patients Considering Active Surveillance

When it comes to Active Surveillance (AS) decisions, there’s good news and bad news. The good news: based on biopsy results, more doctors are recommending AS for prostate cancer (PCa) patients with insignificant disease. The bad news: the biopsy might have missed significant PCa so the patient can’t know for sure if AS is a keep reading

Photodynamic Therapy with TOOKAD®

A new approach to focal treatment for prostate cancer has made its entrance onto the world stage and has patients talking. It is called photodynamic therapy (photo for light, dynamic for action) or PDT. It involves administering a light-sensitive chemical called TOOKAD® by a 10-minute IV injection, which is quickly taken up in the prostate keep reading

Tag: Prostate cancer